PHILADELPHIA, Sept. 25 /PRNewswire/ -- Today, researchers presented new data showing molecular imaging agent 123I-mIBG can help cardiologists define risk in heart failure patients. As an extension of the ADMIRE-HF trial, the ADMIRE-HFX study assessed 123I-mIBG as a risk stratifier for arrhyth